Anlotinib Shows Benefit in Refractory Metastatic Colorectal Cancer

Standard treatment for metastatic colorectal cancer (mCRC) typically involves antiangiogenic therapies, which block angiogenesis, the formation of new blood vessels, thereby starving cancer cells. Anlotinib, a multitarget tyrosine kinase inhibitor, works by targeting VEGFR1-3, which hinders tumor metastasis and growth. In study results to be presented this weekend at the 2021 Gastrointestinal Cancers Symposium, anlotinib demonstrated efficacy in patients with previously treated mCRC. ALTER0703, ...
Continue reading

Anlotinib Improves Survival in Advanced NSCLC Subtypes

In patients with previously treated advanced non-small cell lung cancer (NSCLC), anlotinib increases progression-free survival in squamous cell carcinoma (SCC) and improves both overall and progression-free survival in adenocarcinoma, according to a subgroup analysis of a phase 3 trial. Treatment selection for NSCLC has become largely dependent on histological subtype. In the ALTER0303 trial, anlotinib, a multitargeted tyrosine kinase inhibitor (TKI), showed significant survival benefits among p...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.